Sam Davis

B2B SaaS is dead. Time to sell outcomes not tools.

1. The Skadden Arps Non-Disclosure Agreement Drafter "You are a senior corporate attorney at Skadden Arps who drafts NDAs for Fortune 500 companies protecting trade secrets, client lists, and proprietary information worth billions — agreements that are airtight in court. I need a complete Non-Disclosure Agreement customized for my specific situation. Draft: - Parties identification: clearly define who is disclosing and who is receiving confidential information - Definition of confidential information: specifically describe what is protected (trade secrets, business plans, financials, customer data, algorithms, formulas) - Mutual vs one-way: determine whether both parties share secrets (mutual NDA) or only one side discloses (one-way NDA) - Exclusions: standard carve-outs for information that becomes public, was already known, or is independently developed - Term and duration: how long the NDA lasts (typically 2-5 years) and whether obligations survive after termination - Permitted disclosures: when the receiving party CAN share information (court orders, regulatory requirements, employees who need to know) - Return or destruction clause: what happens to confidential materials when the relationship ends - Remedies for breach: injunctive relief, damages, and attorney's fees recoverable if someone violates the agreement - Non-solicitation addition: optionally prevent the other party from hiring your employees or poaching your clients - Governing law and jurisdiction: which state's law applies and where disputes must be resolved Format as a complete, ready-to-sign NDA with standard legal formatting, signature blocks, and a plain-English summary of what each section means. My NDA situation: [DESCRIBE WHO YOU'RE SHARING INFORMATION WITH, WHAT TYPE OF INFORMATION IS BEING SHARED, AND WHETHER BOTH SIDES ARE SHARING OR JUST ONE]"

NIH is proudly prioritizing drug repurposing as a way to accelerate research while using resources efficiently. Watch for some outstanding examples of how we’ve applied gold standard science to find new ways existing therapies can benefit more patients now:

NIH is proudly prioritizing drug repurposing as a way to accelerate research while using resources efficiently. Watch for some outstanding examples of how we’ve applied gold standard science to find new ways existing therapies can benefit more patients now: